GLOBAL ASSESSMENT OF THE DIAGNOSED PREVALENCE OF CROHN’S DISEASE AND ULCERATIVE COLITIS IN PEDIATRIC POPULATIONS
Author(s)
Shawn X. Sun, PhD1, Olulade Ayodele, MPH, PhD, MD1, Qinghua Li, PhD1, Hongjin Xu, MPH2, Katie Myatt, MS2, Alexandre Vo Dupuy, PharmD, MSc2, Narendra Parihar, BDS, MPH2, Atul Sharma, BDS, MPH2.
1Takeda Development Center Americas, Inc., Cambridge, MA, USA, 2Clarivate Plc, Ann Arbor, MI, USA.
1Takeda Development Center Americas, Inc., Cambridge, MA, USA, 2Clarivate Plc, Ann Arbor, MI, USA.
OBJECTIVES: To estimate the global- and country-specific diagnosed prevalence of Crohn’s disease (CD) and ulcerative colitis (UC) in pediatric populations across 83 countries.
METHODS: A literature review of MEDLINE, Web of Science, and SciELO databases identified population-based studies between 2013 to 2023, inclusive, reporting diagnosed prevalence of CD and/or UC in pediatric patients aged 2 to 17 years. Diagnosed prevalence estimates were identified using study-defined criteria and International Classification of Diseases 9/10 codes. Age-stratification models were used when pediatric age-group data were unavailable. For countries lacking robust, reliable prevalence data, estimates were extrapolated from proxy countries matched by race/ethnicity, geography, and gross domestic product (GDP) per capita. Future prevalence was estimated using birth cohort or GDP-based trend models. Age- and gender-specific prevalent cases were calculated using United Nations population data.
RESULTS: Of the 861 publications reviewed, 238 were included in this analysis. In 2023, the global estimate of diagnosed pediatric prevalent cases of CD and UC was 591,356 (CD: 321,049; UC: 270,307). In 2023, diagnosed pediatric CD prevalence varied widely, ranging from 2-182 per 100,000 population; the highest prevalence was estimated in Czech Republic (182/100,000), Ireland (140/100,000), and Canada (110/100,000), while Algeria, Egypt, and Nigeria (each 2/100,000), had among the lowest prevalence. Diagnosed pediatric UC prevalence was also varied, ranging from 1-203 per 100,000 population in 2023; the highest rates were estimated in Finland (203/100,000), Ireland (137/100,000), and Czech Republic (111/100,000), while Algeria and Egypt (each 2/100,000), and Taiwan (1/100,000) had among the lowest prevalence. Diagnosed prevalent pediatric CD and UC cases were projected to rise to 546,509 and 421,442 in 2045, respectively.
CONCLUSIONS: The global diagnosed prevalence of pediatric CD and UC is pronounced, with marked variation across countries. The projected global rise in CD and UC cases suggests that disease burden will increase in children and adolescents.
METHODS: A literature review of MEDLINE, Web of Science, and SciELO databases identified population-based studies between 2013 to 2023, inclusive, reporting diagnosed prevalence of CD and/or UC in pediatric patients aged 2 to 17 years. Diagnosed prevalence estimates were identified using study-defined criteria and International Classification of Diseases 9/10 codes. Age-stratification models were used when pediatric age-group data were unavailable. For countries lacking robust, reliable prevalence data, estimates were extrapolated from proxy countries matched by race/ethnicity, geography, and gross domestic product (GDP) per capita. Future prevalence was estimated using birth cohort or GDP-based trend models. Age- and gender-specific prevalent cases were calculated using United Nations population data.
RESULTS: Of the 861 publications reviewed, 238 were included in this analysis. In 2023, the global estimate of diagnosed pediatric prevalent cases of CD and UC was 591,356 (CD: 321,049; UC: 270,307). In 2023, diagnosed pediatric CD prevalence varied widely, ranging from 2-182 per 100,000 population; the highest prevalence was estimated in Czech Republic (182/100,000), Ireland (140/100,000), and Canada (110/100,000), while Algeria, Egypt, and Nigeria (each 2/100,000), had among the lowest prevalence. Diagnosed pediatric UC prevalence was also varied, ranging from 1-203 per 100,000 population in 2023; the highest rates were estimated in Finland (203/100,000), Ireland (137/100,000), and Czech Republic (111/100,000), while Algeria and Egypt (each 2/100,000), and Taiwan (1/100,000) had among the lowest prevalence. Diagnosed prevalent pediatric CD and UC cases were projected to rise to 546,509 and 421,442 in 2045, respectively.
CONCLUSIONS: The global diagnosed prevalence of pediatric CD and UC is pronounced, with marked variation across countries. The projected global rise in CD and UC cases suggests that disease burden will increase in children and adolescents.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EPH116
Topic
Epidemiology & Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Gastrointestinal Disorders, SDC: Pediatrics